JP2025011142A5 - - Google Patents

Info

Publication number
JP2025011142A5
JP2025011142A5 JP2024168470A JP2024168470A JP2025011142A5 JP 2025011142 A5 JP2025011142 A5 JP 2025011142A5 JP 2024168470 A JP2024168470 A JP 2024168470A JP 2024168470 A JP2024168470 A JP 2024168470A JP 2025011142 A5 JP2025011142 A5 JP 2025011142A5
Authority
JP
Japan
Prior art keywords
application
invention described
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2024168470A
Other languages
English (en)
Japanese (ja)
Other versions
JP2025011142A (ja
Filing date
Publication date
Priority claimed from JP2021530875A external-priority patent/JP7649239B2/ja
Application filed filed Critical
Publication of JP2025011142A publication Critical patent/JP2025011142A/ja
Publication of JP2025011142A5 publication Critical patent/JP2025011142A5/ja
Pending legal-status Critical Current

Links

JP2024168470A 2018-11-30 2024-09-27 キメラ抗原受容体ファクトリおよびその使用方法 Pending JP2025011142A (ja)

Applications Claiming Priority (6)

Application Number Priority Date Filing Date Title
US201862773885P 2018-11-30 2018-11-30
US62/773,885 2018-11-30
US201962826462P 2019-03-29 2019-03-29
US62/826,462 2019-03-29
JP2021530875A JP7649239B2 (ja) 2018-11-30 2019-12-02 キメラ抗原受容体ファクトリおよびその使用方法
PCT/US2019/064032 WO2020113224A2 (en) 2018-11-30 2019-12-02 Chimeric antigen receptor factories and methods of use thereof

Related Parent Applications (1)

Application Number Title Priority Date Filing Date
JP2021530875A Division JP7649239B2 (ja) 2018-11-30 2019-12-02 キメラ抗原受容体ファクトリおよびその使用方法

Publications (2)

Publication Number Publication Date
JP2025011142A JP2025011142A (ja) 2025-01-23
JP2025011142A5 true JP2025011142A5 (https=) 2025-10-15

Family

ID=70853578

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2021530875A Active JP7649239B2 (ja) 2018-11-30 2019-12-02 キメラ抗原受容体ファクトリおよびその使用方法
JP2024168470A Pending JP2025011142A (ja) 2018-11-30 2024-09-27 キメラ抗原受容体ファクトリおよびその使用方法

Family Applications Before (1)

Application Number Title Priority Date Filing Date
JP2021530875A Active JP7649239B2 (ja) 2018-11-30 2019-12-02 キメラ抗原受容体ファクトリおよびその使用方法

Country Status (7)

Country Link
US (1) US12577311B2 (https=)
EP (1) EP3887509A4 (https=)
JP (2) JP7649239B2 (https=)
KR (1) KR20210135475A (https=)
AU (1) AU2019387566A1 (https=)
CA (1) CA3119644A1 (https=)
WO (1) WO2020113224A2 (https=)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN120795163A (zh) * 2016-10-14 2025-10-17 丹娜法伯癌症研究所公司 模块化四聚体双特异性抗体平台
CN109401969B (zh) * 2018-12-13 2024-02-02 珠海西格膜生物技术有限公司 一种细胞工厂的管道连接系统及其使用方法
EP3983444A4 (en) * 2019-06-14 2023-10-25 Dana-Farber Cancer Institute, Inc. Antibodies against pd-1 and methods of use thereof
WO2020252471A1 (en) * 2019-06-14 2020-12-17 Dana-Farber Cancer Institute, Inc. Antibodies against pd-1 and methods of use thereof
EP4226972A4 (en) * 2020-10-12 2025-01-01 Nanjing Iaso Biotechnology Co., Ltd. CD70-BINDING ANTIBODY AND CHIMERIC ANTIGEN RECEPTORS (CAR) AND THEIR USE
KR20230118887A (ko) 2020-12-03 2023-08-14 센츄리 쎄라퓨틱스 인코포레이티드 유전자 조작 세포 및 이의 용도
US11661459B2 (en) 2020-12-03 2023-05-30 Century Therapeutics, Inc. Artificial cell death polypeptide for chimeric antigen receptor and uses thereof
AR124414A1 (es) 2020-12-18 2023-03-22 Century Therapeutics Inc Sistema de receptor de antígeno quimérico con especificidad de receptor adaptable
CN114565761B (zh) * 2022-02-25 2023-01-17 无锡市第二人民医院 一种基于深度学习的肾透明细胞癌病理图像肿瘤区域的分割方法
JP2025524368A (ja) * 2022-06-09 2025-07-30 テリックス ファーマシューティカルズ (イノベーションズ) ピーティーワイ リミテッド 併用療法
IL322949A (en) * 2023-03-03 2025-10-01 Arsenal Biosciences Inc Systems targeting PSMA and CA9

Family Cites Families (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4797368A (en) 1985-03-15 1989-01-10 The United States Of America As Represented By The Department Of Health And Human Services Adeno-associated virus as eukaryotic expression vector
US4683202A (en) 1985-03-28 1987-07-28 Cetus Corporation Process for amplifying nucleic acid sequences
US5139941A (en) 1985-10-31 1992-08-18 University Of Florida Research Foundation, Inc. AAV transduction vectors
US4946778A (en) 1987-09-21 1990-08-07 Genex Corporation Single polypeptide chain binding molecules
US5091513A (en) 1987-05-21 1992-02-25 Creative Biomolecules, Inc. Biosynthetic antibody binding sites
US5132405A (en) 1987-05-21 1992-07-21 Creative Biomolecules, Inc. Biosynthetic antibody binding sites
US6013516A (en) 1995-10-06 2000-01-11 The Salk Institute For Biological Studies Vector and method of use for nucleic acid delivery to non-dividing cells
US5928906A (en) 1996-05-09 1999-07-27 Sequenom, Inc. Process for direct sequencing during template amplification
US5994136A (en) 1997-12-12 1999-11-30 Cell Genesys, Inc. Method and means for producing high titer, safe, recombinant lentivirus vectors
WO2006089141A2 (en) 2005-02-18 2006-08-24 Dana-Farber Cancer Institute Antibodies against cxcr4 and methods of use thereof
US8466263B2 (en) 2005-12-02 2013-06-18 Dana-Farber Cancer Institute, Inc. Carbonic anhydrase IX (G250) anitbodies
WO2009086514A1 (en) 2007-12-28 2009-07-09 Dana-Farber Cancer Institute, Inc. Humanized monoclonal antibodies and methods of use
WO2011139375A1 (en) * 2010-05-06 2011-11-10 Ludwig Institute For Cancer Research Ltd Antibodies directed against carbonic anhydrase ix and methods and uses thereof
EP2686347B1 (en) * 2011-03-16 2018-05-02 argenx BVBA Antibodies to cd70
CA2861491C (en) 2012-02-13 2020-08-25 Seattle Children's Hospital D/B/A Seattle Children's Research Institute Bispecific chimeric antigen receptors and therapeutic uses thereof
EP3511343A1 (en) 2012-05-04 2019-07-17 Dana Farber Cancer Institute, Inc. Affinity matured anti-ccr4 humanized monoclonal antibodies and methods of use
EP3204418B1 (en) 2014-10-06 2020-03-25 Dana Farber Cancer Institute, Inc. Humanized cc chemokine receptor 4 (ccr4) antibodies and methods of use thereof
US20180334490A1 (en) * 2014-12-03 2018-11-22 Qilong H. Wu Methods for b cell preconditioning in car therapy
CN108064251A (zh) * 2014-12-19 2018-05-22 达纳-法伯癌症研究所公司 碳酸酐酶ix特异性嵌合抗原受体及其使用方法
EP3233900A2 (en) 2014-12-19 2017-10-25 Dana-Farber Cancer Institute, Inc. Chimeric antigen receptors and methods of use thereof
US10738116B2 (en) * 2015-03-19 2020-08-11 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Dual specific anti-CD22-anti-CD19 chimeric antigen receptors
WO2016174652A1 (en) * 2015-04-30 2016-11-03 Technion Research & Development Foundation Limited Chimeric antigen receptors and methods of their use
JP6956639B2 (ja) 2015-05-01 2021-11-02 デイナ ファーバー キャンサー インスティチュート,インコーポレイテッド 抗ccr4抗体を用いてサイトカイン発現を媒介する方法
US10508143B1 (en) 2015-10-30 2019-12-17 Aleta Biotherapeutics Inc. Compositions and methods for treatment of cancer
TWI785009B (zh) * 2017-02-14 2022-12-01 美商凱特製藥公司 Cd70結合分子及使用彼之方法
AU2018225164A1 (en) 2017-02-22 2019-09-19 Aleta Biotherapeutics Inc. Compositions and methods for treatment of cancer
AU2019235900B2 (en) 2018-03-14 2025-12-11 Dana-Farber Cancer Institute, Inc. Engineered cells, T cell immune modulating antibodies and methods for using the same

Similar Documents

Publication Publication Date Title
JP2025027013A5 (https=)
JP2025011142A5 (https=)
JP2024116190A5 (https=)
JP2023115329A5 (https=)
JP2024036694A5 (https=)
JP2024032941A5 (https=)
JP2023171775A5 (https=)
JP2025176106A5 (https=)
JP2022184985A5 (https=)
JP2023166402A5 (https=)
JP2023103258A5 (https=)
JP2024114921A5 (https=)
JP2024161376A5 (https=)
JP2023145572A5 (https=)
JP2025069142A5 (https=)
JP2024150466A5 (https=)
JP2024129139A5 (https=)
JP2023181322A5 (https=)
JP2022024034A5 (https=)
JP2025098156A5 (https=)
JP2024045126A5 (https=)
JP2025094038A5 (https=)
JP2025090801A5 (https=)
JP2024149687A5 (https=)
JP2023502517A5 (https=)